BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC) Files An 8-K Regulation FD Disclosure
Item 7.01
| Regulation FD Disclosure |
Officers and representatives of the Company will present to
various investors and stockholders beginning March 6, 2017 using
the presentation materials furnished as Exhibit 99.1 hereto and
which are incorporated herein by reference.
The information in this report (including Exhibit 99.1) shall not
be deemed to be filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liability of that section, and shall
not be incorporated by reference into any registration statement
or other document filed under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits |
| (d) |
Exhibits. |
| Exhibit | Description |
| No. | |
| 99.1 |
Presentation materials to be used by officers and other representatives of the Company |
2
About BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC)
BioSpecifics Technologies Corp. (BioSpecifics) is a biopharmaceutical company. The Company is engaged in the development of an injectable collagenase clostridium histolyticum (CCH) for multiple indications. The Company has a development and license agreement with Endo International plc (Endo) for injectable collagenases for marketed indications and indications in development. CCH is marketed as XIAFLEX and as XIAPEX in Europe. Its injectable collagenases are marketed for indications, such as Dupuytren’s contracture and Peyronie’s disease. BioSpecifics is conducting development work with respect to human lipoma and uterine fibroids. XIAFLEX and XIAPEX are approved in the United States, the European Union, Switzerland, Canada, Australia and Japan for the treatment of Dupuytren’s contracture. Endo manages the research and development of XIAFLEX for their licensed indications, including frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis and uterine fibroids. BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC) Recent Trading Information
BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC) closed its last trading session up +0.52 at 53.80 with 32,858 shares trading hands.
